31%
Revenue growth
15k+
Instruments in installed base
100+
Countries products sold into
A global leader in the diagnostics of serum protein with a superior technology in electrophoresis. Sebia is a research-driven company covering several pathologies including multiple myeloma, diabetes (HbA1c) and haemoglobin deficiencies. Montagu originally acquired the business in 2006 and invested for a second time in 2014.
A Montagu business
- A global leader in electrophoresis with cutting-edge technology
- Highly recurring revenues
- Strong market dynamics increasing demand and potential to grow emerging market sales
Supporting international expansion
Between 2014 and 2018, we supported Sebia:
- In the successful launch and development of its new generation instrument the Capillarys 3
- Accelerate penetration of the diabetes market
- Complete the strategic acquisition of Italian competitor Interlab
Sebia was sold to a consortium of long term investors: Caisse de dépôt et placement du Québec (CDPQ), Téthys and CVC’s long term fund.
